58 related articles for article (PubMed ID: 21599434)
1. Study on the Clinical Safe and Effective Methods of Arsenic-Containing Compound-Qinghuang Powder in the Treatment of Myelodysplastic Syndrome.
Zhu Q; Deng Z; Zhu S; Zhao P; Wang M; Hu X
Evid Based Complement Alternat Med; 2017; 2017():2095682. PubMed ID: 29348764
[TBL] [Abstract][Full Text] [Related]
2. Iron chelators: as therapeutic agents in diseases.
Salimi Z; Afsharinasab M; Rostami M; Eshaghi Milasi Y; Mousavi Ezmareh SF; Sakhaei F; Mohammad-Sadeghipour M; Rasooli Manesh SM; Asemi Z
Ann Med Surg (Lond); 2024 May; 86(5):2759-2776. PubMed ID: 38694398
[TBL] [Abstract][Full Text] [Related]
3. Causes and Pathophysiology of Acquired Sideroblastic Anemia.
Rodriguez-Sevilla JJ; Calvo X; Arenillas L
Genes (Basel); 2022 Aug; 13(9):. PubMed ID: 36140729
[TBL] [Abstract][Full Text] [Related]
4. The Clinical Significance of Iron Overload and Iron Metabolism in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Weber S; Parmon A; Kurrle N; Schnütgen F; Serve H
Front Immunol; 2020; 11():627662. PubMed ID: 33679722
[TBL] [Abstract][Full Text] [Related]
5. Controversies on the Consequences of Iron Overload and Chelation in MDS.
Vinchi F; Hell S; Platzbecker U
Hemasphere; 2020 Jun; 4(3):e357. PubMed ID: 32647792
[TBL] [Abstract][Full Text] [Related]
6. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management".
Patnaik MM; Tefferi A
Am J Hematol; 2019 Apr; 94(4):475-488. PubMed ID: 30618061
[TBL] [Abstract][Full Text] [Related]
7. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management.
Patnaik MM; Tefferi A
Am J Hematol; 2017 Mar; 92(3):297-310. PubMed ID: 28188970
[TBL] [Abstract][Full Text] [Related]
8. Iron overload-related heart failure in a patient with transfusion-dependent myelodysplastic syndrome reversed by intensive combined chelation therapy.
Pinto V; Balocco M; Ambaglio I; Derchi G; Malcovati L; Forni GL
Clin Case Rep; 2015 Nov; 3(11):952-4. PubMed ID: 26576280
[TBL] [Abstract][Full Text] [Related]
9. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome.
Shenoy N; Vallumsetla N; Rachmilewitz E; Verma A; Ginzburg Y
Blood; 2014 Aug; 124(6):873-81. PubMed ID: 24923296
[TBL] [Abstract][Full Text] [Related]
10. Iron chelation therapy in myelodysplastic syndromes: where do we stand?
Mitchell M; Gore SD; Zeidan AM
Expert Rev Hematol; 2013 Aug; 6(4):397-410. PubMed ID: 23991926
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.
Malcovati L; Hellström-Lindberg E; Bowen D; Adès L; Cermak J; Del Cañizo C; Della Porta MG; Fenaux P; Gattermann N; Germing U; Jansen JH; Mittelman M; Mufti G; Platzbecker U; Sanz GF; Selleslag D; Skov-Holm M; Stauder R; Symeonidis A; van de Loosdrecht AA; de Witte T; Cazzola M;
Blood; 2013 Oct; 122(17):2943-64. PubMed ID: 23980065
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes.
Cermak J; Jonasova A; Vondrakova J; Cervinek L; Belohlavkova P; Neuwirtova R
Leuk Res; 2013 Dec; 37(12):1612-5. PubMed ID: 23937987
[TBL] [Abstract][Full Text] [Related]
13. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
[TBL] [Abstract][Full Text] [Related]
14. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
Ha SY; Chik KW; Ling SC; Lee AC; Luk CW; Lam CW; Ng IO; Chan GC
Hemoglobin; 2006; 30(2):263-74. PubMed ID: 16798652
[TBL] [Abstract][Full Text] [Related]
15. Combined therapy with deferoxamine and deferiprone.
Kattamis A
Ann N Y Acad Sci; 2005; 1054():175-82. PubMed ID: 16339663
[TBL] [Abstract][Full Text] [Related]
16. Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes.
Goldberg SL
Leuk Res; 2007 Dec; 31 Suppl 3():S16-22. PubMed ID: 18037414
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome.
Cermak J; Jonasova A; Vondrakova J; Walterova L; Hochova I; Siskova M; Neuwirtova R
Hemoglobin; 2011; 35(3):217-27. PubMed ID: 21599434
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
